Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel
Tal Brosh‐Nissimov, Efrat Orenbuch‐Harroch, Michal Chowers, et al.
Clinical Microbiology and Infection (2021) Vol. 27, Iss. 11, pp. 1652-1657
Open Access | Times Cited: 337

Showing 1-25 of 337 citing articles:

Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis
Caifang Zheng, Weihao Shao, Xiaorui Chen, et al.
International Journal of Infectious Diseases (2021) Vol. 114, pp. 252-260
Open Access | Times Cited: 577
Diagnostics for COVID-19: moving from pandemic response to control
Rosanna W. Peeling, Dominique Heymann, Yik-Ying Teo, et al.
The Lancet (2021) Vol. 399, Iss. 10326, pp. 757-768
Open Access | Times Cited: 384
Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US
Jing Sun, Qulu Zheng, Vithal Madhira, et al.
JAMA Internal Medicine (2021) Vol. 182, Iss. 2, pp. 153-153
Open Access | Times Cited: 238
COVID-19 and metabolic disease: mechanisms and clinical management
Charlotte Steenblock, Peter E. H. Schwarz, Barbara Ludwig, et al.
The Lancet Diabetes & Endocrinology (2021) Vol. 9, Iss. 11, pp. 786-798
Open Access | Times Cited: 206
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
Yu‐Chyi Hwang, Ruei‐Min Lu, Shih-Chieh Su, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 194
Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization
Dennis Lapuente, Jana Fuchs, Jonas Willar, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 183
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
Annika Fendler, Elisabeth G.E. de Vries, Corine H. GeurtsvanKessel, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 6, pp. 385-401
Open Access | Times Cited: 178
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations
Rebecca Grainger, Alfred H.J. Kim, Richard Conway, et al.
Nature Reviews Rheumatology (2022) Vol. 18, Iss. 4, pp. 191-204
Open Access | Times Cited: 159
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study
Annika Fendler, Scott T.C. Shepherd, Lewis Au, et al.
Nature Cancer (2021) Vol. 2, Iss. 12, pp. 1305-1320
Open Access | Times Cited: 158
Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs
Stephanie Seneff, Greg Nigh, Anthony M. Kyriakopoulos, et al.
Food and Chemical Toxicology (2022) Vol. 164, pp. 113008-113008
Open Access | Times Cited: 149
COVID-19-Associated Hospitalizations Among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States, January 2021 to April 2022
Fiona P. Havers, Huong Pham, Christopher A. Taylor, et al.
JAMA Internal Medicine (2022) Vol. 182, Iss. 10, pp. 1071-1071
Open Access | Times Cited: 149
A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies
Monika Kumari, Ruei‐Min Lu, Mu‐Chun Li, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 111
Delta Variants of SARS-CoV-2 Cause Significantly Increased Vaccine Breakthrough COVID-19 Cases in Houston, Texas
Paul A. Christensen, Randall J. Olsen, Sheng Long, et al.
American Journal Of Pathology (2021) Vol. 192, Iss. 2, pp. 320-331
Open Access | Times Cited: 110
Artificial intelligence-assisted colorimetric lateral flow immunoassay for sensitive and quantitative detection of COVID-19 neutralizing antibody
Haoyang Tong, Chaoyu Cao, Minli You, et al.
Biosensors and Bioelectronics (2022) Vol. 213, pp. 114449-114449
Open Access | Times Cited: 82
IgG4 Antibodies Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS-CoV-2 Spike Protein
Vladimir N. Uversky, Elrashdy M. Redwan, William Makis, et al.
Vaccines (2023) Vol. 11, Iss. 5, pp. 991-991
Open Access | Times Cited: 78
Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine–induced antibody and T cell immunity and function
Joseph J. Sabatino, Kristen Mittl, William Rowles, et al.
JCI Insight (2022) Vol. 7, Iss. 4
Open Access | Times Cited: 75
Oral antiviral treatments for COVID-19: opportunities and challenges
Laila Rahmah, Sunny O. Abarikwu, Amanuel Godana Arero, et al.
Pharmacological Reports (2022) Vol. 74, Iss. 6, pp. 1255-1278
Open Access | Times Cited: 70
Innate Immune Suppression by SARS-CoV-2 mRNA Vaccinations: The role of G-quadruplexes, exosomes and microRNAs
Stephanie Seneff, Greg Nigh, Anthony M. Kyriakopoulos, et al.
Authorea (Authorea) (2022)
Open Access | Times Cited: 69
COVID-19 Vaccine Boosters: The Good, the Bad, and the Ugly
Piotr Rzymski, Carlos A. Camargo, Andrzej Fal, et al.
Vaccines (2021) Vol. 9, Iss. 11, pp. 1299-1299
Open Access | Times Cited: 76
Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults
Addi J. Romero‐Olmedo, Axel Schulz, Svenja Hochstätter, et al.
Nature Microbiology (2022) Vol. 7, Iss. 2, pp. 195-199
Open Access | Times Cited: 63
Imaging and Clinical Features of COVID-19 Breakthrough Infections: A Multicenter Study
Jong Eun Lee, Minhee Hwang, Yun‐Hyeon Kim, et al.
Radiology (2022) Vol. 303, Iss. 3, pp. 682-692
Open Access | Times Cited: 61
Glycaemic control is associated with SARS-CoV-2 breakthrough infections in vaccinated patients with type 2 diabetes
Raffaele Marfella, Celestino Sardu, Nunzia D’Onofrio, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 54
Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months
Caroline M. Hsu, Daniel E. Weiner, Harold J. Manley, et al.
Clinical Journal of the American Society of Nephrology (2022) Vol. 17, Iss. 3, pp. 403-413
Open Access | Times Cited: 53
Length of hospital stay and risk of intensive care admission and in-hospital death among COVID-19 patients in Norway: a register-based cohort study comparing patients fully vaccinated with an mRNA vaccine to unvaccinated patients
Robert Whittaker, Anja Bråthen Kristofferson, Beatriz Valcárcel Salamanca, et al.
Clinical Microbiology and Infection (2022) Vol. 28, Iss. 6, pp. 871-878
Open Access | Times Cited: 47
SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry
Jean W. Liew, Milena Gianfrancesco, Carly Harrison, et al.
RMD Open (2022) Vol. 8, Iss. 1, pp. e002187-e002187
Open Access | Times Cited: 47
Page 1 - Next Page

Scroll to top